| Filed On | Filing |
|---|---|
| 08 Oct 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability |
| 08 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation
This Employment Agreement (the “Agreement”) is entered into by and between AngioDynamics, Inc, a Delaware corporation (the “Company”) and Eric Honroth (“Executive”) (together, the “Parties” and individually, a “Party”). |
| 14 Jul 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability |
| 23 Apr 2026 |
8-K: Other Events
On April 23, 2026, AngioDynamics, Inc. (the “Company” or “AngioDynamics”) filed a complaint commencing a patent infringement lawsuit in the United States District Court for the District of Delaware against Endovascular Engineering, Inc. ... |
| 02 Apr 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability |
| 03 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
This Transition and Retirement Agreement (the “Agreement”) is dated as of February 3, 2026, by and between AngioDynamics, Inc. a Delaware corporation (the “Company”) and James C. Clemmer (the “Executive”). |
| 14 Jan 2026 |
8-K: Regulation FD Disclosure
J.P. Morgan 44th Annual Healthcare Conference January 14, 2026 Jim Clemmer, President & CEO |
| 06 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability |
| 12 Nov 2025 |
8-K: Submission of Matters to a Vote of Security Holders
The Annual Meeting of Shareholders of AngioDynamics, Inc. (“AngioDynamics”) was held on November 10, 2025. |
| 02 Oct 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum |
| 15 Jul 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
AngioDynamics Reports Strong Fiscal Year 2025 Fourth Quarter and Full Year Financial Results; Continued Execution Driving Accelerated, Profitable Growth |
| 28 May 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
CREDIT AGREEMENT dated as of May 28, 2025 (as it may be amended or modified from time to time, this “Agreement”) among ANGIODYNAMICS, INC., a Delaware corporation (“AngioDynamics”), as Borrower, the other Loan Parties party hereto, the L... |
| 02 Apr 2025 |
8-K: Regulation FD Disclosure
INVESTOR EVENT Shaping the Future of Cardiovascular Care: Innovative Technologies. Improved Outcomes. |
| 02 Apr 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results |
| 16 Jan 2025 |
8-K: Regulation FD Disclosure
J.P. Morgan 43rd Annual Healthcare Conference January 16, 2025 Jim Clemmer, President & CEO |
| 08 Jan 2025 |
8-K: Regulation FD Disclosure
2 2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future fin... |
| 08 Jan 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results |
| 15 Nov 2024 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 03 Oct 2024 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results |
| 16 Jul 2024 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
LATHAM, N.Y.--(BUSINESS WIRE)--Jul. 16, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment ... |
Loading...